ALK Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma14
EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y	Lorlatinib	Predictive	C	Supports Resistance	4	accepted	EID843 Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK S1206Y	Ceritinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1343 Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensi… (full text at CIViC) PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Non-Small Cell Carcinoma14

EML4::ALK Fusion AND ALK L1198F AND ALK C1156Y

Lorlatinib

Predictive

Supports Resistance

accepted

EID843

Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK S1206Y

Ceritinib

Predictive

Supports Sensitivity Response

accepted

EID1343

Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensi… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

Malignant Colorectal Neoplasm1
EML4::ALK Fusion	Nivolumab	Predictive	C	Does Not Support Resistance	3	submitted	EID7482 One patient with colorectal cancer harboring MSI-High and EML4-ALK rearrangement received Nivolumab and achieved a durable response. PMID 29370427 · Pietrantonio et al., 2017 · Open in CIViC	civic

Malignant Colorectal Neoplasm1

EML4::ALK Fusion

Nivolumab

Predictive

Does Not Support Resistance

submitted

EID7482

One patient with colorectal cancer harboring MSI-High and EML4-ALK rearrangement received Nivolumab and achieved a durable response.

PMID 29370427 · Pietrantonio et al., 2017 · Open in CIViC

civic

Malignant Neoplasm35
EML4::ALK Fusion AND ALK C1156Y	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11078 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK C1156Y	Crizotinib	Predictive	D	Supports Resistance	3	submitted	EID7613 Cells expressing EML4-ALK with the resistance mutation C1156Y were resistant to the ALK inhibitor crizotinib in vitro. In cell survival assays Ba/F3 cells with C1156Y treated with crizotinib had an IC… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK C1156Y	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11069 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK C1156Y	Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes	Predictive	D	Does Not Support Resistance	4	submitted	EID7609 In vitro experiments showed that cells expressing EML4-ALK with the resistance mutation C1156Y were sensitive to second and third generation ALK inhibitors. In cell survival assays Ba/F3 cells with C1… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK E1210K	Crizotinib	Predictive	D	Supports Resistance	2	submitted	EID11066 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174C	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11079 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174C	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11072 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174L	Alectinib	Predictive	D	Does Not Support Resistance	2	submitted	EID12666 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to alectinib treatment (IC50: … (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174L	ALK Inhibitor ASP3026	Predictive	D	Supports Resistance	2	submitted	EID12676 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated increased resistance to ASP3026 treatment (IC50: 1… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174L	AZD3463	Predictive	D	Does Not Support Resistance	2	submitted	EID12682 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 15… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1174L	Crizotinib	Predictive	D	Does Not Support Resistance	2	submitted	EID12655 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to crizotinib treatment (IC50:… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1245C	Crizotinib	Predictive	D	Supports Resistance	2	accepted	EID1337 A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizoti… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK F1245C	Crizotinib	Predictive	D	Supports Resistance	3	submitted	EID11067 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R	Alectinib	Predictive	D	Supports Resistance	3	accepted	EID1350 Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reporte… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R	Brigatinib	Predictive	D	Supports Resistance	3	accepted	EID1351 This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation w… (full text at CIViC) PMID 25727400 · Fontana et al., 2015 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R	Lorlatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7593 Ba/F3 cells expressing the EML4-ALK fusion with the G1202R resistance mutation were sensitive to lorlatinib in a cell viability assay. However, cells expressing variant 1 of EML4-ALK (E13; A20) had sl… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R AND ALK L1196M	Alectinib + Brigatinib + Ceritinib + Crizotinib + LorlatinibSubstitutes	Predictive	D	Supports Resistance	4	submitted	EID7592 EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1196M were found to be resistant to lorlatinib as well as first and second-line ALK inhibitors. H3122 lung cancer cell lines… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1202R AND ALK L1198F	Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes	Predictive	D	Supports Resistance	4	submitted	EID7595 EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1198F were found to be resistant to lorlatinib as well as second-line ALK inhibitors. Ba/F3 cells expressing variant 1 (E13;… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269A	Alectinib	Predictive	D	Supports Resistance	2	submitted	EID12669 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated increased resistance to alectinib treatment (IC50:… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269A	AZD3463	Predictive	D	Does Not Support Resistance	2	submitted	EID12680 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 11… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269A	Brigatinib	Predictive	D	Does Not Support Resistance	2	submitted	EID12672 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated similar sensitivity to AP26113 treatment (IC50: 4.… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269A	Crizotinib	Predictive	D	Supports Resistance	2	submitted	EID4621 In an in vitro study, a FL5.12 cell line expressing NPM1-ALK or EML4-ALK (known sensitizing alterations to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (I… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269S	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11077 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK G1269S	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11075 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171S	Alectinib	Predictive	D	Supports Resistance	2	submitted	EID12670 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to alectinib treatment (IC50:… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171S	ALK Inhibitor ASP3026	Predictive	D	Supports Resistance	2	submitted	EID12675 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to ASP3026 treatment (IC50: 2… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171S	AZD3463	Predictive	D	Supports Resistance	2	submitted	EID12679 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to AZD3463 treatment (IC50: 3… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171S	Brigatinib	Predictive	D	Supports Resistance	2	submitted	EID12671 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to AP26113 treatment (IC50: 2… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171S	Ceritinib	Predictive	D	Supports Resistance	2	submitted	EID12657 In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to ceritinib treatment (IC50:… (full text at CIViC) PMID 27009859 · Amin et al., 2016 · Open in CIViC	civic
EML4::ALK Fusion AND ALK I1171T	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11071 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1152V	Crizotinib	Predictive	D	Supports Resistance	3	submitted	EID11070 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1196M	ALK Inhibitor TAE684	Predictive	D	Supports Sensitivity Response	3	submitted	EID11080 From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1196M	Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes	Predictive	D	Supports Sensitivity Response	4	submitted	EID7597 Ba/F3 cells expressing EML4-ALK variant 1 (E13; A20) or variant 3 (E6a; A20) with the L1196M resistance mutation were sensitive to second and third generation ALK inhibitors. Cell viability assays sho… (full text at CIViC) PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1196M	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID7598 In vitro experiments showed Ba/F3 cells expressing EML4-ALK variant 1 (E13; A20) or 3 (E6a; A20) with the L1196M ALK mutation were resistant to crizotinib (IC50 313.4 +/- 50.1 and 333.1 +/- 62.1). PMID 29650534 · Yoda et al., 2018 · Open in CIViC	civic
EML4::ALK Fusion AND ALK L1196M	Crizotinib	Predictive	D	Supports Resistance	4	submitted	EID11073 Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC) PMID 22034911 · Zhang et al., 2011 · Open in CIViC	civic

Malignant Neoplasm35

EML4::ALK Fusion AND ALK C1156Y

ALK Inhibitor TAE684

Predictive

Supports Sensitivity Response

submitted

EID11078

From a mutation assay that generated crizotinib resistant mutations in EML4::ALK, the five most resistant mutations found were introduced into Ba/F3 cells and tested with the ALK inhibitor TAE684. EML… (full text at CIViC)

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK C1156Y

Crizotinib

Predictive

Supports Resistance

submitted

EID7613

Cells expressing EML4-ALK with the resistance mutation C1156Y were resistant to the ALK inhibitor crizotinib in vitro. In cell survival assays Ba/F3 cells with C1156Y treated with crizotinib had an IC… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK C1156Y

Crizotinib

Predictive

Supports Resistance

submitted

EID11069

Ba/F3 cells with EML4::ALK were subjected to mutagen N-ethyl-N-nitrosourea and then incubated without IL3 in 250, 500, 720, 1000, 1440, or 2000 nm crizotinib. The ten most frequently seen mutants we… (full text at CIViC)

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK C1156Y

Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes

Predictive

Does Not Support Resistance

submitted

EID7609

In vitro experiments showed that cells expressing EML4-ALK with the resistance mutation C1156Y were sensitive to second and third generation ALK inhibitors. In cell survival assays Ba/F3 cells with C1… (full text at CIViC)

PMID 26698910 · Shaw et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK E1210K

Crizotinib

Predictive

Supports Resistance

submitted

EID11066

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174C

ALK Inhibitor TAE684

Predictive

Supports Sensitivity Response

submitted

EID11079

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174C

Crizotinib

Predictive

Supports Resistance

submitted

EID11072

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174L

Alectinib

Predictive

Does Not Support Resistance

submitted

EID12666

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to alectinib treatment (IC50: … (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174L

ALK Inhibitor ASP3026

Predictive

Supports Resistance

submitted

EID12676

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated increased resistance to ASP3026 treatment (IC50: 1… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174L

AZD3463

Predictive

Does Not Support Resistance

submitted

EID12682

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 15… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1174L

Crizotinib

Predictive

Does Not Support Resistance

submitted

EID12655

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK F1174L co-mutation, demonstrated similar sensitivity to crizotinib treatment (IC50:… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1245C

Crizotinib

Predictive

Supports Resistance

accepted

EID1337

A Ba/F3 cell line expressing EML4-ALK variant 1 was created, and then exposed to the DNA modifying agent ENU. Cells were subsequently cultured in 96 well plates at increasing concentrations of crizoti… (full text at CIViC)

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK F1245C

Crizotinib

Predictive

Supports Resistance

submitted

EID11067

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R

Alectinib

Predictive

Supports Resistance

accepted

EID1350

Ba/F3 cell line expressing EML4-ALK variant 3 with G1202R ALK mutation was assessed for alectinib sensitivity and IC50 for survival of 868 nM was reported, which was 64.4x higher than the IC50 reporte… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R

Brigatinib

Predictive

Supports Resistance

accepted

EID1351

This study compared drug responses in Ba/F3 cells expressing either EML4-ALK or NPM-ALK fusions, with or without G1202R ALK mutation. Cells expressing the EML4-ALK variant 3 with G1202R ALK mutation w… (full text at CIViC)

PMID 25727400 · Fontana et al., 2015 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R

Lorlatinib

Predictive

Supports Sensitivity Response

submitted

EID7593

Ba/F3 cells expressing the EML4-ALK fusion with the G1202R resistance mutation were sensitive to lorlatinib in a cell viability assay. However, cells expressing variant 1 of EML4-ALK (E13; A20) had sl… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R AND ALK L1196M

Alectinib + Brigatinib + Ceritinib + Crizotinib + LorlatinibSubstitutes

Predictive

Supports Resistance

submitted

EID7592

EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1196M were found to be resistant to lorlatinib as well as first and second-line ALK inhibitors. H3122 lung cancer cell lines… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1202R AND ALK L1198F

Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes

Predictive

Supports Resistance

submitted

EID7595

EML4-ALK expressing Ba/F3 cell lines with the compound ALK mutation G1202R/L1198F were found to be resistant to lorlatinib as well as second-line ALK inhibitors. Ba/F3 cells expressing variant 1 (E13;… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269A

Alectinib

Predictive

Supports Resistance

submitted

EID12669

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated increased resistance to alectinib treatment (IC50:… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269A

AZD3463

Predictive

Does Not Support Resistance

submitted

EID12680

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated similar sensitivity to AZD3463 treatment (IC50: 11… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269A

Brigatinib

Predictive

Does Not Support Resistance

submitted

EID12672

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK G1269A co-mutation, demonstrated similar sensitivity to AP26113 treatment (IC50: 4.… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269A

Crizotinib

Predictive

Supports Resistance

submitted

EID4621

In an in vitro study, a FL5.12 cell line expressing NPM1-ALK or EML4-ALK (known sensitizing alterations to crizotinib) and an ALK G1269A co-mutation, demonstrated resistance to crizotinib treatment (I… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269S

ALK Inhibitor TAE684

Predictive

Supports Sensitivity Response

submitted

EID11077

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK G1269S

Crizotinib

Predictive

Supports Resistance

submitted

EID11075

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171S

Alectinib

Predictive

Supports Resistance

submitted

EID12670

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to alectinib treatment (IC50:… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171S

ALK Inhibitor ASP3026

Predictive

Supports Resistance

submitted

EID12675

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to ASP3026 treatment (IC50: 2… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171S

AZD3463

Predictive

Supports Resistance

submitted

EID12679

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171S

Brigatinib

Predictive

Supports Resistance

submitted

EID12671

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171S

Ceritinib

Predictive

Supports Resistance

submitted

EID12657

In an in vitro study, a FL5.12 cell line expressing EML4-ALK (known sensitizing alteration to crizotinib) and an ALK I1171S co-mutation, demonstrated increased resistance to ceritinib treatment (IC50:… (full text at CIViC)

PMID 27009859 · Amin et al., 2016 · Open in CIViC

civic

EML4::ALK Fusion AND ALK I1171T

Crizotinib

Predictive

Supports Resistance

submitted

EID11071

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK L1152V

Crizotinib

Predictive

Supports Resistance

submitted

EID11070

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK L1196M

ALK Inhibitor TAE684

Predictive

Supports Sensitivity Response

submitted

EID11080

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

EML4::ALK Fusion AND ALK L1196M

Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID7597

Ba/F3 cells expressing EML4-ALK variant 1 (E13; A20) or variant 3 (E6a; A20) with the L1196M resistance mutation were sensitive to second and third generation ALK inhibitors. Cell viability assays sho… (full text at CIViC)

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK L1196M

Crizotinib

Predictive

Supports Resistance

submitted

EID7598

In vitro experiments showed Ba/F3 cells expressing EML4-ALK variant 1 (E13; A20) or 3 (E6a; A20) with the L1196M ALK mutation were resistant to crizotinib (IC50 313.4 +/- 50.1 and 333.1 +/- 62.1).

PMID 29650534 · Yoda et al., 2018 · Open in CIViC

civic

EML4::ALK Fusion AND ALK L1196M

Crizotinib

Predictive

Supports Resistance

submitted

EID11073

PMID 22034911 · Zhang et al., 2011 · Open in CIViC

civic

Evidence by cancer (118 items)

Clinical significance (0)